{"id":544269,"date":"2021-05-21T21:28:02","date_gmt":"2021-05-21T21:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=544269"},"modified":"2021-05-21T21:28:02","modified_gmt":"2021-05-21T21:28:02","slug":"autistic-disorder-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-curemark-gw-pharmaceuticals-zynerba-pharmaceuticals-brainstorm-cell-therapeutics-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/autistic-disorder-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-curemark-gw-pharmaceuticals-zynerba-pharmaceuticals-brainstorm-cell-therapeutics-and-many-others_544269.html","title":{"rendered":"Autistic Disorder Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Curemark, GW Pharmaceuticals, Zynerba Pharmaceuticals, BrainStorm Cell Therapeutics and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1621574633.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Autistic Disorder Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Curemark, GW Pharmaceuticals, Zynerba Pharmaceuticals, BrainStorm Cell Therapeutics and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1621574633.jpeg\" alt=\"Autistic Disorder Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Curemark, GW Pharmaceuticals, Zynerba Pharmaceuticals, BrainStorm Cell Therapeutics and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Autistic Disorder Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Autistic Disorder<\/strong> is a broad term used to describe a group of neurodevelopmental&nbsp;<strong>disorders<\/strong>. These&nbsp;<strong>disorders<\/strong>&nbsp;are characterized by problems with communication and social interaction. People with ASD often demonstrate restricted, repetitive, and stereotyped interests or patterns of behavior.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/autistic-disorder-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Autistic Disorder Pipeline<\/a> Insight, 2021,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about <strong>20+ companies and 30+ pipeline drugs<\/strong> in Autistic Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Autistic Disorder Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Curemark<\/li>\n<li>GW Pharmaceuticals<\/li>\n<li>Zynerba Pharmaceuticals<\/li>\n<li>BrainStorm Cell Therapeutics<\/li>\n<li>Jaguar Gene Therapy<\/li>\n<li>Confluence Pharmaceuticals<\/li>\n<li>Finch Therapeutics<\/li>\n<li>AbbVie<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/autistic-disorder-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/autistic-disorder-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Autistic Disorder report covers around 30+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III and<\/li>\n<li>Mid-stage products (Phase II and<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/autistic-disorder-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Autistic Disorder Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CM-AT<\/li>\n<li>Zygel<\/li>\n<li>CBDV<\/li>\n<li>ML-004<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/autistic-disorder-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/autistic-disorder-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Autistic Disorder Treatment Scenario and Autistic Disorder Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Autistic Disorder drugs?<\/li>\n<li>How many Autistic Disorder drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for Autistic Disorder?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Autistic Disorder therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Autistic Disorder and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/autistic-disorder-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/autistic-disorder-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder&ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">CM-AT: Curemark<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">CBDV: GW Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ML-004: MapLight Therapeutics<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Autologous MSC-NTF cellular therapy: BrainStorm Cell Therapeutics<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder Key Companies<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder Key Products<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder Analyst Views<\/p>\n<p style=\"text-align: justify;\">Autistic Disorder Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/autistic-disorder-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=autistic-disorder-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-curemark-gw-pharmaceuticals-zynerba-pharmaceuticals-brainstorm-cell-therapeutics-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/autistic-disorder-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/autistic-disorder-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/autistic-disorder-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=autistic-disorder-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-curemark-gw-pharmaceuticals-zynerba-pharmaceuticals-brainstorm-cell-therapeutics-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Autistic Disorder Pipeline Autistic Disorder is a broad term used to describe a group of neurodevelopmental&nbsp;disorders. These&nbsp;disorders&nbsp;are characterized by problems with communication and social interaction. People with ASD often demonstrate restricted, repetitive, and stereotyped interests or patterns of behavior. DelveInsight&rsquo;s,&nbsp;&ldquo;Autistic &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/autistic-disorder-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-curemark-gw-pharmaceuticals-zynerba-pharmaceuticals-brainstorm-cell-therapeutics-and-many-others_544269.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-544269","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=544269"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/544269\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=544269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=544269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=544269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}